来源：长江日报 长江日报记者从武汉市医保局获悉，《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》 （下称"新版国家医保药品目录"）及《商业健康保险创新药品目录（2025年）》（下称"商保创新药目 录"）于今日（2026年1月1日）起在武汉同步落地。 新版目录以"临床急需、价格亲民、保障多元"为核心，新增114种药品精准覆盖肿瘤、罕见病等关键领 域，首推的商保创新药目录与基本医保目录形成保障互补。 本次新版目录在武汉落地实施后，"双通道"目录同步扩容，武汉通过明确医疗机构配备标准、搭建院企 常态化对接平台等举措，确保谈判药品"买得到、用得上、报得了"。 50 种创新药 " 快进 " 医保 平均降价超六成 据介绍，本次新版国家医保药品目录调整后，共收录药品3253种，其中西药1857种、中成药1396种。此 次新增的114种药品中，50种为一类创新药，纳入成功率高达88%，且90%以上是近5年获批上市的新 药，实现创新药"快进"医保的加速度。 这些新药精准聚焦临床急需，涵盖肿瘤用药36种、罕见病用药10种、慢性病用药12种、儿童用药9种， 既有治疗三阴性乳腺癌的芦康沙妥珠单抗、全身型重症肌无力的艾加 ...

Core Insights - Novo Nordisk has submitted applications to the FDA for the approval of icodec insulin for the treatment of type 2 diabetes and Mim8 for the treatment of hemophilia A [1] Group 1: Icodec Insulin - Icodec insulin is a long-acting insulin formulation designed based on oral insulin OI338, with a half-life of 196 hours [2] - The design modifications include replacing an 18C fatty acid with a 20C fatty acid to enhance binding affinity to human serum albumin, and substituting Tyr with His at position 16 of the B chain to reduce affinity to human insulin receptors [2] - The initial BLA submission in April 2023 included indications for both type 1 and type 2 diabetes, but the FDA advisory committee found insufficient data for type 1 diabetes, leading to a narrowed indication for type 2 diabetes in the resubmission [2] Group 2: Mim8 - Mim8 is a bispecific antibody developed using Genmab's DuoBody technology, designed to mimic the action of coagulation factor VIIIa (FVIIIa) and bridge factors IXa (FIXa) and X (FX) [3] - It exhibits approximately 15 times the coagulation activity compared to emicizumab [3] - Hemophilia A, affecting around 80%-85% of the estimated 1.125 million hemophilia patients globally, is caused by a deficiency or defect in FVIII [3] Group 3: Hemophilia Treatment Landscape - There are currently 46 approved hemophilia drugs globally, with only 8 being non-factor therapies [4] - Among these, several drugs have been approved specifically for hemophilia A patients, including concizumab, valoctocogene roxaparvovec, emicizumab, marstacimab, and fitusiran [4]